Suven Life gets 3 product patents in Canada, Japan and Korea

With new parents, Suven has 18 granted patents from Canada, 16 from Japan and 16 from South Korea

Suven Life Sciences Limited, a Hyderabad-based biopharmaceutical company, has received a product patent each from Canada, Japan and Korea corresponding to the new chemical entities (NCEs) for the treatment of disorders associated with neuro-degenerative diseases. These patents are valid through 2030.

In a filing to the BSE on Tuesday, Suven Life said the granted claims of the patent included the class of selective 5-HT compounds discovered by Suven and were being developed as therapeutic agents and were used in the treatment of cognitive impairment associated with neurodegenerative disorders like Alzheimer’s, attention deficiency hyperactivity disorder (ADHD), Huntington’s, Parkinson and schizophrenia.

With these new parents, Suven has 18 granted patents from Canada, 16 from Japan and 16 from South Korea. These granted patents are exclusive intellectual property of Suven. Products out of these innovations may be out-licensed at various phases of clinical development like at Phase-I and Phase-II, the company said.

Suven Life's scrip is currently trading at Rs 296.35 on the BSE, up 6.01 per cent, over the previous close of Rs 279.55 a share.